Teleflex Completes Patient Enrollment for Clinical Study of Freesolve Scaffold in Long Coronary Lesions

07:06 AM EDT, 10/12/2026 (MT Newswires) -- Teleflex (TFX) has completed patient enrollment for the BIOMAG-LL clinical study of Freesolve resorbable magnesium scaffold for the treatment of de novo coronary lesions of up to 38 millimeters, the company said Monday. The study enrolled 102 patients across 14 centers in Europe to assess the safety and clinical performance of 35 millimeters and 40 millimeters of the scaffold product, the company said. The study's primary endpoint is target lesion failure rate at 12 months. Follow-up assessments are scheduled at one, six, 12, 36 and 60 months after the procedure, Teleflex said. Clinical follow-ups are scheduled up to 60 months after the procedure, the company added. Teleflex said Freesolve is commercially available in countries that accept CE marking.